20.109 MOD3 Research Proposal: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 50: Line 50:
#*Elution with unattached promoter sequence?
#*Elution with unattached promoter sequence?
#*Elution using G/B Binding Buffer I?
#*Elution using G/B Binding Buffer I?
#*Nrf binding to Prx1 promoter
#**binds to (-536 -> -528) proximal and to (-1429 -> -1421) distal region of Prx1 promoter
#**these are the electrophile/antioxidant responsive element
#Sequence isolated phage
#*mix E.Coli on LB XGal/AMP +IPTG plates
#*white colonies contain the insert
#pick and sequence colonies


==<font color = purple><b>Publications</b></font color>==
==<font color = purple><b>Publications</b></font color>==

Revision as of 10:38, 10 May 2008

Maryelise Cieslewicz
Kyle Atmore


"Peroxiredoxin 1 PDB image"

Logistics

Prepare a 12 minute powerpoint talk that describes the research question you have identified, how you propose to study the question and what you hope to learn. A general outline your research proposal presentation is:

  • a brief project overview
  • sufficient background information for everyone to understand your proposal
  • a statement of the research problem and goals
  • project details and methods
  • predicted outcomes if everything goes according to plan and if nothing does
  • needed resources to complete the work
  • societal impact if all goes well

Topic

  • Peroxiredoxin inhibition to facilitate cancer therapy

Topic Background

  • Prx's are mostly found in the cytosol (also found in mitochondria, chloroplasts, and peroxisomes).
  • Prx's exhibit antioxidant behavior through peroxidase activity, reducing organic hydroperoxides.
  • Many cancer cells and tissues show increased expression levels of both Prx1 and Prx2.
  • Expression of both Prx's in cancer cells has been associated with increased resistance to standard cancer treatments.
    • Prx1 expression may be used as a predictive indicator of relative risk of death or patient survival among cancer patients.
  • Prx1 may be useful as a new therapeutic target in cancer treatments.

Research Ideas

  • For overall cancer treatment, cells with increased expression levels of Prx1 could be targeted with therapies that inhibited Prx1 expression.
  • Nuclear related factor 2
    • Upregulated by hypoxia
    • Binds Prx1 promoter and induces Prx1 expression
  • Our idea: we want to find Nrf2 mutants with higher binding affinity to prx1 promoter, but result in decrease expression of Prx1. The idea is that such a mutant could be used to competitively inhibit the binding of wild type Nrf2 in cancer cells to the Prx1 promoter, and result in decreased expression of Prx1.
    • create library of Nrf2 mutants
    • Use phage display to test binding affinities of the library of Nrf mutants to the Prx1 promoter
    • Isolate the mutants with relatively (to WT) higher binding affinity for Prx1 promoter
    • Test these mutants to find one or more that in the presence of the Prx1 promoter in cell, show a decrease in Prx1 expression
  • We are still confused about how during phage display individual phage with different mutants attached could be isolated. Most papers just say "phage mutants were isolated" but do not explain how.

Protocol

  1. Get Nrf2 gene plasmid from Invitrogen
    • Contains XhoI and EcoRI restriction sites
  2. Error-prone PCR on isolated gene sequence
  3. Ligate mutants to phagemid plasmid DNA(LITMUS-NEB)
  4. Transform plasmid into supE E. Coli strain XL1-Blue
    • TAG supressed as a glutamine in this strain
  5. Perform multiple binding affinity tests
    • Streptavidin coated beads conjugated with Prx1 promoter sequence
    • Elution with unattached promoter sequence?
    • Elution using G/B Binding Buffer I?
    • Nrf binding to Prx1 promoter
      • binds to (-536 -> -528) proximal and to (-1429 -> -1421) distal region of Prx1 promoter
      • these are the electrophile/antioxidant responsive element
  6. Sequence isolated phage
    • mix E.Coli on LB XGal/AMP +IPTG plates
    • white colonies contain the insert
  7. pick and sequence colonies

Publications

  1. "Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target."[1]
  2. "Structure, mechanism and regulation of peroxiredoxins."[2]
  3. "Oxidation of archaeal peroxiredoxin involves a hypervalent sulfur intermediate."[3]
  4. "Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA)"[4]
  5. "Taenia solium: antioxidant metabolism enzymes as targets for cestocidal drugs and vaccines."[5]
  6. "Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis." [6]
  7. "Peroxiredoxins, a novel protein family in lung cancer"[7]
  8. "Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced proliferation of human MCF-7 breast cancer cells."[8]
  9. "Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression"[9]
  10. "Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer."[10]
  11. "Human prx1 Gene Is a Target of Nrf2 and Is Up-regulated by Hypoxia/Reoxygenation: Implication to Tumor Biology"[11]
  12. "Bach1 Competes with Nrf 2 Leading to Negative Regulation of the Antioxidant Response Element (ARE)-mediated NAD(P)H:Quinone oxidoreductase 1 Gene Expression and Induction in Response to Antioxidants*"
  13. DNA conjugated beads PPT: [12]

Web Pages

  1. Wikipedia - [13]
  2. Sigma Phagemid DNA: [14]
  3. Invitrogen Nrf DNA: [15]
  4. NE Biolabs small peptide: [16]
  5. NE Biolabs LITMUS: [17]
  6. Sequencing Mutants: [18]